XLRN On Watch, BPMC Makes An Imprint, Osteoporosis Drug Evenity Faces FDA Panel

Today's Daily Dose brings you news about miRagen's phase I trial results of Cobomarsen in mycosis fungoides patients; MEDALIST trial results; Apellis Pharma's paroxysmal nocturnal hemoglobinuria study results; Blueprint Medicines' EXPLORER trial results, and Celyad's progress in phase I trial of non-gene edited allogeneic CAR-T therapy.

from RTT - Biotech https://ift.tt/2rjyOR2
via IFTTT